All pharmaceutical industy news tagged with ‘CoviVac’. CoviVac is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Center which is an institute of the Russian Academy of Sciences. It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia. It has not yet gone through a phase III clinical trial as of early March 2021.
Information Internet project PharmProm.Net dedicated to the pharmaceutical industry in the world. It contains a contact base of organizations, enterprises, companies associated with the pharmaceutical market. The editorial staff of the PharmProm.Net portal offers cooperation in the field of information promotion and advertising in the pharmaceutical market.